Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

10-year CHD Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer Patients Taking Aromatase Inhibitors

NCT00885612 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00885612
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00885612 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
10-year CHD Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer Patients Taking Aromatase Inhibitors
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
May 31, 2009
Completion date
March 31, 2010
Enrollment
1,114 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer